UK markets closed

Champions Oncology, Inc. (CSBR)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
5.02-0.04 (-0.79%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 68.78M
Enterprise value 72.06M
Trailing P/E 458.00
Forward P/E 22.88
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.39
Price/book (mrq)6.77
Enterprise value/revenue 1.46
Enterprise value/EBITDA -10.59

Trading information

Stock price history

Beta (5Y monthly) 0.40
52-week change 32.85%
S&P500 52-week change 321.08%
52-week high 37.32
52-week low 34.17
50-day moving average 35.34
200-day moving average 35.82

Share statistics

Avg vol (3-month) 34.08k
Avg vol (10-day) 32.57k
Shares outstanding 513.59M
Implied shares outstanding 613.7M
Float 84.72M
% held by insiders 125.55%
% held by institutions 142.22%
Shares short (15 Apr 2024) 456.51k
Short ratio (15 Apr 2024) 417.26
Short % of float (15 Apr 2024) 40.82%
Short % of shares outstanding (15 Apr 2024) 40.42%
Shares short (prior month 15 Mar 2024) 462.58k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:12
Last split date 312 Aug 2015

Financial highlights

Fiscal year

Fiscal year ends 30 Apr 2023
Most-recent quarter (mrq)31 Jan 2024

Profitability

Profit margin -19.76%
Operating margin (ttm)-21.44%

Management effectiveness

Return on assets (ttm)-17.48%
Return on equity (ttm)-388.65%

Income statement

Revenue (ttm)49.22M
Revenue per share (ttm)3.63
Quarterly revenue growth (yoy)-5.90%
Gross profit (ttm)N/A
EBITDA -6.33M
Net income avi to common (ttm)-9.73M
Diluted EPS (ttm)-0.72
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)4.47M
Total cash per share (mrq)0.33
Total debt (mrq)7.74M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.60
Book value per share (mrq)-0.15

Cash flow statement

Operating cash flow (ttm)-5.01M
Levered free cash flow (ttm)-3.13M